| Trial ID: | L4840 |
| Source ID: | NCT06762314
|
| Associated Drug: |
Insulin
|
| Title: |
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Insulin|DRUG: Semaglutide|DRUG: Empagliflozin
|
| Outcome Measures: |
Primary: The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment., The primary outcome of this trial is the change in glycated haemoglobin from baseline after 3 months of treatment., 3 months |
|
| Sponsor/Collaborators: |
Sponsor: Mostafa Bahaa | Collaborators: Meshal Saud Alotaibi, Senior Clinical Pharmacist, King Salman Speicialist Hospital-Hail, K.S.A.|Sahar Kamal Hegazy, Professor of Clinical Pharmacy, Faculty of Pharmacy - Tanta University|Sahar Mohamed Elhaggar, Professor of Clinical Pharmacy Faculty of Pharmacy - Tanta University|Prof. Wael Farag Mohammed, Professor of Internal Medicine, Faculty of Medicine-Tanta University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
105
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2025-01-20
|
| Completion Date: |
2028-11-20
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-25
|
| Locations: |
Tanta Unuversity, Tanta, 31527, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT06762314
|
